Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening

Transfusion

Volumn 53, Issue 6, 2013, Pages 1217-1225

  Soucie, J Michael ^a   De Staercke, Christine ^a   Monahan, Paul E ^a   Recht, Michael ^a   Chitlur, Meera B ^a   Gruppo, Ralph ^a   Hooper, W Craig ^a   Kessler, Craig ^a   Kulkarni, Roshni ^a   Manco Johnson, Marilyn J ^a   Powell, Jerry ^a   Pyle, Meredith ^a   Riske, Brenda ^a   Sabio, Hernan ^a   Trimble, Sean ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; NUCLEIC ACID; VIRUS ANTIBODY;

ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; FEMALE; HEMOPHILIA; HUMAN; HUMAN PARVOVIRUS B19; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SCREENING TEST; SEROPREVALENCE; VIRUS TRANSMISSION;

ALGORITHMS; BLOOD BANKS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASES, EMERGING; DNA, VIRAL; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFECTION CONTROL; LOGISTIC MODELS; MALE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES;

EID: 84877700550     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03907.x     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38: 81-8, 93-7.
2. de Jong EP, Walther FJ, Kroes AC, Oepkes D,. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn 2011; 31: 419-25.
3. Lamont RF, Sobel JD, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, Uldbjerg N, Romero R,. Parvovirus B19 infection in human pregnancy. BJOG 2010; 118: 175-86.
4. Colmegna I, Alberts-Grill N,. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin North Am 2009; 35: 95-110.
5. Tzang BS, Tsai CC, Tsay GJ, Wang M, Sun YS, Hsu TC,. Anti-human parvovirus B19 nonstructural protein antibodies in patients with rheumatoid arthritis. Clin Chim Acta 2009; 405: 76-82.
6. Nocton JJ, Miller LC, Tucker LB, Schaller JG,. Human parvovirus B19-associated arthritis in children. J Pediatr 1993; 122: 186-90.
7. Murai C, Munakata Y, Takahashi Y, Ishii T, Shibata S, Muryoi T, Funato T, Nakamura M, Sugamura K, Sasaki T,. Rheumatoid arthritis after human parvovirus B19 infection [letter]. Ann Rheum Dis 1999; 58: 130-32.
8. Altschuler EL,. Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning. Lancet 1999; 354: 1026-7.
9. Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, Saitoh T, Sawai T, Sugamura K, Sasaki T,. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95: 8227-32.
10. Kishore J, Misra R, Gupta D, Ayyagari A,. Raised IgM antibodies to parvovirus B19 in juvenile rheumatoid arthritis. Indian J Med Res 1998; 107: 15-8.
11. Kleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D, Kiss JE, Shyamala V, Busch MP,; National Heart, Lung, Blood Institute Retrovirus Epidemiology Donor Study (REDS-II). Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007; 47: 1756-64.
12. Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J,. Parvovirus in plasma pools and plasma derivatives. Vox Sang 2001; 81: 228-35.
13. Azzi A, Morfini M, Mannucci PM,. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194-204.
14. Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M, Musso R, Santoro R, Schiavoni M,. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization. Transfusion 1997; 37: 517-22.
15. Soucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB,; the Universal Data Collection Project Working Group. Human parvovirus B19 in young males with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion 2004; 44: 1179-85.
16. Zakrzewska K, Azzi A, De Biasi E, Radossi P, De Santis R, Davoli PG, Tagariello G,. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 2001; 65: 402-7.
17. Allain JP, Thomas I, Sauleda S,. Nucleic acid testing for emerging viral infections. Transfus Med 2002; 12: 275-83.
18. Wu C, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MW,. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005; 45: 1003-10.
19. Geng Y, Wu C, Bhattacharyya SP, Tan D, Guo Z, Yu MW,. Parvovirus B19 in factor VIII concentrates; effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007; 47: 883-9.
20. Soucie JM, McAlister S, McClellan A, Oakley M, Su Y,. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010; 38 Suppl: S475-81.
21. Soucie JM, Wang C, Forsyth A, Funk S, Denney M, Roach KE, Boone D,; the Hemophilia Treatment Center Network. Range of motion measurements: reference values and a database for comparison studies. Haemophilia 2011; 17: 500-7.
22. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-72.
23. LeFrere JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S,. Persistent B19 infection in immune competent individuals: implications for transfusion safety. Blood 2005; 106: 2890-5.
24. Doyle S, Corcoran A,. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. J Infect Dis 2006; 194: 154-8.
25. Young NS, Brown KE,. Parvovirus B19. N Engl J Med 2004; 350: 586-97.
26. Cassinotti P, Siegl G, Michel BA, Bruhlmann P,. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. J Med Virol 1998; 56: 199-204.
27. Lu J, Zhi N, Wong S, Brown KE,. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006; 193: 582-90.
28. Ray NB, Nieva DR, Seftor EA, Khalkhali-Ellis Z, Naides SJ,. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum 2001; 44: 1582-6.
29. Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P,. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012; 52: 1482-9.
30. Soucie JM, Richardson LC, Evatt B, Linden J, Ewenstein BM, Stein S, Leissinger C, Manco-Johnson M, Sexauer C,; the Hemophilia Surveillance System Project Investigators. Risk factors for infection with hepatitis B and hepatitis C viruses in a large cohort of hemophilic males. Transfusion 2001; 41: 338-43.